MX2017013489A - Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos. - Google Patents

Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos.

Info

Publication number
MX2017013489A
MX2017013489A MX2017013489A MX2017013489A MX2017013489A MX 2017013489 A MX2017013489 A MX 2017013489A MX 2017013489 A MX2017013489 A MX 2017013489A MX 2017013489 A MX2017013489 A MX 2017013489A MX 2017013489 A MX2017013489 A MX 2017013489A
Authority
MX
Mexico
Prior art keywords
uric acid
blood levels
lowering blood
methods
same
Prior art date
Application number
MX2017013489A
Other languages
English (en)
Inventor
Wei-Shu Lu
Oscar Iii Brown Carl
Lim Hanpin
Kuen CHUNG Tien-
Kuang CHEN Chi-
Original Assignee
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Biotechnology Inc filed Critical Twi Biotechnology Inc
Publication of MX2017013489A publication Critical patent/MX2017013489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

Se provee una formulación de liberación controlada que contiene diacereína o sus análogos; también se provee un método para la reducción de los niveles en sangre de ácido úrico usando esta formulación; en una modalidad, la invención provee una formulación de liberación controlada con efectos secundarios adversos reducidos y/o mayor biodisponibilidad, que comprende una capa de liberación inmediata y una capa de liberación prolongada.
MX2017013489A 2015-04-20 2015-04-20 Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos. MX2017013489A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/026678 WO2016171656A1 (en) 2015-04-20 2015-04-20 Formulations containing diacerein and methods of lowering blood levels of uric acid using the same

Publications (1)

Publication Number Publication Date
MX2017013489A true MX2017013489A (es) 2018-05-22

Family

ID=57143313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013489A MX2017013489A (es) 2015-04-20 2015-04-20 Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos.

Country Status (12)

Country Link
EP (1) EP3285754A4 (es)
JP (1) JP2018513203A (es)
KR (1) KR20180013880A (es)
CN (1) CN107708681A (es)
AU (1) AU2015392441A1 (es)
BR (1) BR112017022509A2 (es)
CA (1) CA2983394A1 (es)
CO (1) CO2017011722A2 (es)
IL (1) IL255073A0 (es)
MX (1) MX2017013489A (es)
RU (1) RU2690372C2 (es)
WO (1) WO2016171656A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
CN101031322A (zh) * 2004-10-01 2007-09-05 日本脏器制药株式会社 固体药物制剂
EP2167048B1 (en) * 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
US20100285114A1 (en) * 2007-09-27 2010-11-11 Rahul Dabre Pharmaceutical compositions of rhein or diacerein
CA2709236A1 (en) * 2007-09-27 2009-04-02 Wockhardt Research Centre Pharmaceutical compositions of rhein or diacerein
WO2009048940A2 (en) * 2007-10-08 2009-04-16 Dr. Reddy's Laboratories Ltd. Diacerein pharmaceutical formulations
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
KR101190708B1 (ko) * 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
PE20130574A1 (es) * 2010-06-16 2013-06-01 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
KR20140007247A (ko) * 2010-06-22 2014-01-17 티더블유아이 파머수티컬스, 인코포레이티드 음식물 영향이 감소된 제어 방출 조성물
CN103429236B (zh) * 2011-03-11 2016-09-21 安成生物科技股份有限公司 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物

Also Published As

Publication number Publication date
EP3285754A1 (en) 2018-02-28
CN107708681A (zh) 2018-02-16
JP2018513203A (ja) 2018-05-24
IL255073A0 (en) 2017-12-31
CO2017011722A2 (es) 2018-04-19
KR20180013880A (ko) 2018-02-07
BR112017022509A2 (pt) 2018-07-17
RU2690372C2 (ru) 2019-06-03
RU2017140079A (ru) 2019-05-20
AU2015392441A1 (en) 2017-11-09
RU2017140079A3 (es) 2019-05-20
WO2016171656A1 (en) 2016-10-27
EP3285754A4 (en) 2018-12-19
CA2983394A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
AU2024202345A1 (en) Nucleic acid carriers and therapeutic methods of use
EP3407973A4 (en) BIOLOGICALLY ACTIVE CANNABIDIOL ANALOGS
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
EP3288520A4 (en) Use of active agents during chemical treatments
GT201700179A (es) Formulaciones en polvo nasal para el tratamiento de hipoglicemia
AU2014375637A1 (en) Formula of neuregulin preparation
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
WO2017127835A3 (en) Aqueous formulations and methods of preparation and use thereof
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
PH12018501072A1 (en) Modified release orally administered amino acid formulations
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
IL289052A (en) Tests and methods for detecting nucleic acids
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
ECSP18055921A (es) Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal
IL285921A (en) Intravenous formulation including estrogens for the treatment of acute heart failure
EP3611170A4 (en) ANXIOLYTIC COMPOUNDS BY DEUTERATION AND MEDICAL APPLICATIONS
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
ECSP16086196A (es) Sales farmacéuticamente aceptables de enantiomeros de pirlindole para uso en medicina
MX2017016346A (es) Metodos de tratamiento con taselisib.
EP3548648A4 (en) FLUORINE ACID COMPOUNDS, COMPOSITIONS AND METHOD OF USE
MX2017013489A (es) Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos.
EP3425388A4 (en) METHOD OF EVALUATING PAIN CAUSED BY ADMINISTRATION OF DRUG SOLUTION, METHOD OF SELECTING DRUG SOLUTION DELIVERY
WO2015168102A3 (en) Prolonged protein stabilization by resveratrol
EP3996679C0 (en) HIGH CONCENTRATION INSULIN FORMULATION
EP4019965A4 (en) METHOD FOR DETERMINING THE CONCENTRATION OF A PERACETIC ACID FORMULATION